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reproduction in any medium, provided the original author and source are credited.SUMMARYHuman pluripotent stem cells (hPSCs) could provide an infinite source of clinically relevant cells with potential applications in regener-
ative medicine. However, hPSC lines vary in their capacity to generate specialized cells, and the development of universal protocols for
the production of tissue-specific cells remains a major challenge. Here, we have addressed this limitation for the endodermal lineage by
developing a defined culture system to expand and differentiate human foregut stem cells (hFSCs) derived from hPSCs. hFSCs can self-
renewwhilemaintaining their capacity to differentiate into pancreatic and hepatic cells. Furthermore, near-homogenous populations of
hFSCs can be obtained from hPSC lines which are normally refractory to endodermal differentiation. Therefore, hFSCs provide a unique
approach to bypass variability between pluripotent lines in order to obtain a sustainable source of multipotent endoderm stem cells for
basic studies and to produce a diversity of endodermal derivatives with a clinical value.INTRODUCTION
The development of a universal protocol to differentiate
any hPSC line into a homogenous population of a specific
cell type has been rendered difficult by the inherent vari-
ability that exists between lines. Epigenetic memory,
inconsistent reprogramming, and genetic background are
likely to be the main cause of this variability, which repre-
sents a major challenge for the development of personal-
ized medicines (Lund et al., 2012) and for modeling
diseases with a low-penetrance phenotype. The expansion
of intermediate stages of differentiation could represent an
attractive alternative to address this issue, especially if these
cell types can be isolated from a heterogeneous population.
For example, neuronal stem cells can be easily expanded
from human induced pluripotent stem cell (hIPSC) lines
differentiated toward the neuroectoderm lineage and
then differentiated into a diversity of neurons, thereby by-
passing the need to continuously grow pluripotent cells
(Falk et al., 2012). However, the same approach with endo-
derm differentiation has been more problematic because
the complex combination of inductive signals controlling
the specification and patterning of this germ layer can be
difficult to mimic in vitro (Sneddon et al., 2012). Following
gastrulation, definitive endoderm migrates to form the
primitive gut, which initially consists of a single flattenedStem Cellsheet of cells surrounded by mesoderm. Simultaneously,
as migration is occurring, the primitive gut is becoming
regionalized along the dorsal-ventral and anterior-poste-
rior axes into foregut, midgut, and hindgut domains (Wells
and Melton, 1999). This patterning is induced by the
surrounding mesoderm, which secretes a variety of growth
factors not limited to activin, Wnt, fibroblast growth factor
(FGF), and bonemorphogenetic protein (BMP) signal path-
ways (Deutsch et al., 2001; Zaret, 2002). The effects of these
signaling pathways can be observed at the molecular level
with distinct expression patterns of genes such as SOX2 in
the foregut and CDX2 in the hindgut, while early PDX1
expression marks the midgut (Zorn and Wells, 2009). It is
from the foregut region that many of the major organ
systems develop such as the liver, thyroid, lungs, the upper
airways, the billary system, stomach, and pancreas. The in-
duction of these organs is orchestrated by a complex
combination of morphogen gradients secreted by other
developing organ systems such as the cardiac mesoderm
(Lemaigre and Zaret, 2004). The exact nature of these con-
centration gradients remains difficult to reproduce faith-
fully in vitro, but several groups (including our own)
have made significant progress in understanding how
different signaling pathways impact the foregut endoderm
cells (Cho et al., 2012). To date, no one has described a
foregut cell type that possesses the proliferative andReports j Vol. 1 j 293–306 j October 15, 2013 j ª2013 The Authors 293
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mammalian gut tube.
To address this challenge, we have developed a defined
culture system to derive human foregut stem cells (hFSCs)
from hPSCs. These stem cells can self-renew in vitro and
resemble multipotent cells of the anterior primitive gut
tube by their capacity to differentiate into pancreatic and
hepatic cells. Furthermore, hFSCs can be easily derived
from hIPSC lines resistant to endoderm differentiation,
thereby enabling the production of endodermal derivatives
from a broad number of hPSC lines.RESULTS
Anteroposterior Patterning of Definitive Endoderm
Cells Generated from hPSCs Is Controlled by Activin/
TGF-b and WNT Signaling Pathways
Our group has developed a defined culture system to direct
the differentiation of hPSCs into a near-homogenous pop-
ulation of definitive endoderm (DE) cells that have the
capacity to differentiate into hepatocytes and pancreatic
progenitors (Brown et al., 2011; Cho et al., 2012; Rashid
et al., 2010; Touboul et al., 2010; Vallier et al., 2009a;
Yusa et al., 2011). Cells grown in these culture conditions
successively express primitive streak markers (T and
Mixl1), downregulate pluripotency markers (NANOG,
SOX2, and POU5F1) and progressively upregulate definitive
endoderm markers (CXCR4, FOXA2, GATA4, CERB, and
SOX17) (Figures S1A–S1C available online). Flow cyto-
metry analyses showed that 80% of the resulting DE
population coexpresses CXCR4 and SOX17 (Figure S1D).
Interestingly, the resulting population of DE cells is nega-
tive for genes marking the foregut (SOX2), the midgut/
hindgut (CDX2), the pancreas (PDX1), the liver (AFP),
and the lungs (HOXA1) (Figures S1E and S1F) This confirms
that DE cells generated in vitro could correspond to early
endoderm progenitor cells prior to anteroposterior
patterning or organogenesis.
We next examined the capacity of DE cells to differen-
tiate into representatives of the anterior and posterior do-
mains of the primitive gut tube. We screened various
growth factors (data not shown) and found that activin-A
blocksCDX2 expressionwhile inducing expression of ante-
rior gut markers such as SOX2, HHEX, and HOXA3 (Figures
1A and 1B; data not shown). On the other hand, DE cells
grown in the presence of the GSK3b inhibitor CHIR99021
express midgut/hindgut markers such as CDX2 and
HOXC5 (Figures 1C and 1D) and show no expression of
anterior markers. During both activin-A treatment and
CHIR treatment, cells express high levels of the primitive
gut markers GATA4, HNF4a, EpCAM, and HOXA2, demon-
strating that cells retain their endodermal identity under294 Stem Cell Reports j Vol. 1 j 293–306 j October 15, 2013 j ª2013 The Athese conditions (data not shown). Of note, flow cytometry
analyses revealed that 90% of the cells express SOX2 after
activin-A treatment while 85% of the cells were positive
for CDX2 after CHIR99021 treatment (Figures 1E and 1F).
Similar results were obtained using two hIPSC lines
(BBHX8 and A1ATD.1) (Figures S2A–S2H). Taken together,
these data show that activin-A and GSK3beta signaling
direct the anteroposterior patterning of humanDE in vitro.
Hindgut/Midgut CDX2-Expressing Cells Generated
from hPSCs Can Differentiate into Gut-like Organoids
To further validate the identity of the cells generated in the
presence of activin-A or CHIR99021, we decided to test
their capacity to differentiate into intestinal cells. SOX2+
cells and CDX2+ cells were grown into 3D organoid culture
conditions (Spence et al., 2011) known to promote poste-
rior gut differentiation. SOX2+ cells grown under these
conditions ceased to proliferate and could not be expanded
(data not shown), whereas CDX2+ cells formed spheroids
with highly folded structures resembling intestinal epithe-
lium (Figures 2A and 2B). Gut organoids expressed intesti-
nal markers (mucin, villin, and chromagranin A) and could
be expanded for more than 2 months while displaying a
progressive increase in the markers of adult intestinal
epithelium (Figure 2C). Finally, comparative immunocyto-
chemistry analysis of CDX2+ cell-derived organoids with
primary mouse intestinal organoids demonstrated a polar-
ized epithelium with apical villin expression in both types
of organoids (Figure 2D). These data confirm that CDX2+
cells generated in the presence of CHIR99021 have the dif-
ferentiation potential to formmidgut/hindgut progenitors,
while activin-A-induced SOX2+ cells have lost this capacity.
These SOX2+ cells could consequently be equivalent to
foregut progenitors (Arnold et al., 2011).
Foregut Cells Generated from hPSCs Can Be Expanded
for a Prolonged Period of Time in Defined Culture
Medium
We then tested the capacity of foregut SOX2+ cells to self-
renew in vitro. DE cells derived from human embryonic
stem cells (hESCs) were differentiated for 4 days in the pres-
ence of activin-A and were subsequently cultured in the
presence of a diverse combination of growth factors (data
not shown). Following this approach, we identified that
the combination of activin-A, basic fibroblast growth factor
(bFGF), BMP4, hepatocyte growth factor (HGF), and
epidermal growth factor (EGF) was sufficient to expand
foregut SOX2+ cells for more than 20 passages (Figure 3A).
DE cells grown under these conditions form a simple
epithelium (Figure 3B) that can be serially passaged at a
plating density of 40–50 3 106 cells/cm2 of plate surface
area. Foregut cells grown in these culture conditions ex-
press homogenously the proliferationmarker Ki67 (Figuresuthors
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Figure 1. Activin and GSK3/WNT Control Anteroposterior Patterning of Definitive Endoderm In Vitro
(A and B) Quantitative PCR (qPCR) and immunocytochemistry analyses show that DE cells grown for 5 days in the presence of activin-A
express foregut anterior endoderm markers (SOX2 and HHEX) without expressing hindgut markers (CDX2 and HOXC5).
(C and D) qPCR and immunocytochemistry analyses show that DE cells grown for 5 days in the presence of GSK3-beta inhibitor CHIR99021
express posterior endoderm markers (CDX2 and HOXC5) without expressing anterior markers (SOX2 and HHEX).
(E and F) Fluorescence-activated cell sorting (FACS) analyses showing that DE cells derived from hESCs and grown for 5 days in the presence
of activin express the anterior marker SOX2, while DE cells grown in the presence of CHIR99021 express the hindgut marker CDX2. Scale
bars, 100 mm.
Error bars represent SEM. See also Figure S1.
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Multipotent Foregut Cells from Pluripotent Cells3C and 3D), retained a normal karyotype (Figure 3E), and
after 20 passages have an expansion potential of more
than 4.2 3 108-fold (Figure 3F). Importantly, these culture
conditions were only supportive of foregut cells, because
significant cell death was observed with neuronal-like
and fibroblast-like cells. This selection could explain how
a near-homogenous population of foregut cells could be
easily obtained only after few passages (Figure S3A). After
more than ten passages in these culture conditions, foregutStem CellSOX2+ cells did not express transcripts or proteins of plu-
ripotency (POU5f1 and NANOG), lung (NKX2.1), hepatic
(AFP), or pancreatic (PDX1) markers while maintaining
the expression of foregut markers (HNF4a, SOX17,
CXCR4, EpCAM, HNF1b, GATA4, Cer, SOX2, HNF6, and
HNF1beta; Figures 3G, 3H, and S3B–S3D). Flow cytometry
analyses showed that SOX17 and CXCR4were coexpressed
near homogenously (Figure S3A) along with other foregut
markers such as CXCR4/HNF4a (>90% double positive),Reports j Vol. 1 j 293–306 j October 15, 2013 j ª2013 The Authors 295
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Figure 2. Hindgut Endoderm Generated from hPSCs Can Differentiate into Intestinal Derivatives When Grown in 3D Conditions
(A and B) Hindgut CDX2-positive cells generated by growing DE cells in the presence of CHIR99021 for 5 days were grown in 3D cultures
conditions to generate highly folded spheres resembling mature (A) and immature (B) gut organoids.
(C) Accordingly, the resulting organoids could be grown for 2 months while progressively increasing the expression of gut markers (OLFM4,
CHGA, MUC2, Villin, and KRT19).
(D) Morphological similarities between gut organoid derived from hPSCs and primary mouse intestinal epithelial organoid cultures. Scale
bars, 100 mm.
Error bars represent SEM. See also Figure S1.
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GATA4 (>90% double positive; Figure 3I). Importantly,
similar results were obtained with two hIPSC lines
(BBHX8 and A1ATD.1; Figures S3A–S3D) (Brown et al.,
2011; Rashid et al., 2010; Vallier et al., 2009a). Finally, we
observed that foregut cells could be frozen after five pas-
sages and then thawed to be expanded for at least five addi-
tional passages without any loss in gene expression profiles
or observable loss of proliferation capacity (data not shown
and Figure S4A). Together, these data demonstrate that our
culture system captures a homogenous population of fore-
gut cells that can self-renew in vitro and are lineage
restricted to endodermal tissue and thus could be represen-
tative of an endodermal stem cell (referred thereafter as hu-
man foregut stem cells or hFSCs).
hFSCs CanDifferentiate into Cells Expressing Hepatic,
Pancreatic, and Lung/Thyroid Markers
To further characterize hFSCs, we decided to investigate
their spontaneous capacity to differentiate in endodermal
derivatives. For that, 1.0 3 105 hFSCs were transplanted
under the kidney capsule of nonobese diabetic severe com-
bined immunodeficiency (NOD-SCID) mice and incubated
in vivo for 10 weeks. Both hESC- and hIPSC-derived hFSCs
produced very large cysts with very limited solid outgrowth
(Figure 4A). Histological examination revealed that hFSCs
did not produce teratomas, as there were no tissues repre-
sentative of the ectoderm and mesoderm lineages. Instead,
the outgrowths were formed mainly of cyst resembling
glandular tissue and lung epithelium (Figure 4B). Accord-
ingly, immunostaining analyses indicated that a large296 Stem Cell Reports j Vol. 1 j 293–306 j October 15, 2013 j ª2013 The Amajority of cells contained in hFSCs-derived outgrowth ex-
pressed the lung/thyroid marker Nkx2.1, while fewer
pockets of cells expressing liver (AFP/EpCAM) and pancre-
atic marker (PDX1) could also be detected (Figure 4C).
However, cells expressing mesoderm (Brachyury) or neuro-
ectoderm (N-CAM) markers were never observed and the
hindgut marker CDX2 was also absent (Figure 4C)
Together, these data suggest that hFSCs have the capacity
to differentiate into liver, pancreas, and lung/thyroid cells
and thus could be considered as multipotent stem cells.
To confirm this hypothesis, we tested the ability of hFSCs
to differentiate into liver and pancreatic cells using culture
systems recently developed by our group to produce these
cells types directly from hPSCs (Cho et al., 2012; Rashid
et al., 2010). hFSCs grown in culture conditions inductive
for pancreatic specification (Cho et al., 2012) (Figure 5A)
sequentially expressed early pancreatic markers (HLXB9
and PDX1), then endocrine progenitor marker (NGN3),
and finally beta cell marker (c-peptide/insulin) (Figure 5B).
As reported previously, more than 90% of cells were PDX1
positive at stage 4 of the pancreatic differentiation protocol
(Figures S4B and S4C) (Cho et al., 2012). After 25 days of
differentiation, cells expressing c-peptide, PDX1, glucagon
(GCG), and somatostatin (SST) could be observed by
immunocytochemistry and c-peptide release was detected
upon glucose stimulation (Figures 5C and 5D). Impor-
tantly, approximately 15%–20% of pancreatic cells were
positive for C-peptide and 10%–20% of these C-peptide-
positive cells were polyhormonal (i.e., coexpressing both
C-peptide and either GCG [20%] or SST [10%]) (Fig-
ure S4D–S4G). While surprising, these result are inuthors
Stem Cell Reports
Multipotent Foregut Cells from Pluripotent Cellsagreement with our previous study showing that mono-
hormonal/glucose-responsive cells could be generated
from hPSCs using a defined culture system (Cho et al.,
2012). Importantly, further characterization beyond the
scope of the current study will be necessary to validate
the real functionality of the insulin-expressing cells gener-
ated under our culture conditions. Similar analyses were
performed using our liver differentiation protocol and
hFSCs described previously (Hannan et al., 2013; Rashid
et al., 2010; Yusa et al., 2011) (Figure 5E). Under these con-
ditions, hFSCs rapidly differentiate into a near-homoge-
nous population of hepatocyte-like cells expressing liver
markers (AFP, ALB, A1AT, HNF4a, and CK18; Figure 5F
and 5G). In addition, a vast majority of hepatocyte-like
cells (90%) coexpressed albumin and ASGPR and alpha-1-
antitrypsin as reported previously (Figures S4H–S4K) (Ra-
shid et al., 2010; Hannan et al., 2013). Further functional
characterization also showed that these cells could uptake
low-density lipoprotein (Figure 5H) and cardiogreen from
tissue culturemedium (Figure S6) and secrete AATand albu-
min (data not shown and Figure 5I). Importantly, multiple
hFSC lines derived from different hIPSC lines displayed
similar differentiation efficiency (Figures S5 and S6), while
frozen/thawed hFSCs could also generate liver and pancre-
atic cells. Indeed, defrosted hFSCs could be expanded for
five passages and then differentiate efficiently into cells ex-
pressing pancreatic (PDX1 > 90%) and hepatic (AFP > 90%)
markers (Figures S4J–S4M). Taken together, these data
demonstrate that hFSCs have the capacity to differentiate
into foregut derivatives including lung/thyroid, pancreatic,
and hepatic cells, thereby confirming that they are
multipotent.
Clonal Differentiation of hFSCs Confirms Their
Multipotency
To further reinforce these results, we decided to confirm
that single hFSC are multipotent. hFSCs grow as an epithe-
lium and single-cell isolation systematically resulted in cell
death, thereby excluding conventional clonal assays. To
bypass this limitation, we generated GFP-expressing hFSCs
that were dissociated into single cells and individually
placed on a well of a 24-well plate containing non-GFP-ex-
pressing hFSCs (Figures 6A and 6B). The following day,
wells containing a single GFP-positive hFSC were marked
for expansion, and after five passages, the resulting cells
were differentiated into hepatic and pancreatic cells. Of
note, such an approach, while not strictly clonal, did allow
us to follow the expansion of a single GFP cell and assess
the differentiation potential of its progeny. Indeed, GFP-
positive hFSC cells grown in these respective culture condi-
tions expressed hepatic (ALB, A1AT, AFP, and HNF4a and
low-density lipoprotein [LDL] uptake) and pancreatic
(PDX1, INS, NGN3, and SST) markers, thereby providingStem Cellthe necessary evidence that hFSCs generated from hESCs
and hIPSCs (data not shown; Figures 6C and 6D) are multi-
potent stem cells.
Generation of hFSCs Bypasses Variability between
hIPSC Lines
hIPSC lines can be easily generated from a broad number of
patients, and this has opened the possibility to model a di-
versity of disorders for basic studies and drug screening.
However, recent reports have shown that hIPSC lines can
vary in their capacity to generate cell types with clinical
value. The precise mechanisms responsible for this vari-
ability remain unclear but are likely to combine several or-
igins, including epigenetic memory, genetic background,
and abnormal reprogramming. This variability also pre-
sents a major challenge for personalized cell-based therapy
and large-scale genetic studies, because each hIPSC line
might require protocol optimization. Accordingly, we
recently analyzed the capacity of 48 hIPSC lines derived
from 16 individuals to differentiate into endoderm, and
while a majority of hIPSC lines could differentiate in our
culture system, we identified three endoderm-resistant
hIPSC lines (COXS8, COXV3, and Line4). These lines pro-
duced less than 30%of SOX17-positiveDE cells (Figure 7A).
Importantly, this heterogeneity precluded further differen-
tiation toward the pancreatic/hepatic lineages. We there-
fore decided to isolate hFSCs from these endoderm-resis-
tant hIPSC lines. For that, heterogeneous endoderm cells
generated from the hIPSC lines COXS8, COXV3, and
Line4 were grown for 3 additional days in the presence of
activin-A to promote foregut specification and the resulting
cells were transferred into culture conditions supporting
hFSCs expansion. Interestingly, contaminating cells of
nonendodermal origin stopped proliferating and progres-
sively disappeared upon passaging. Flow cytometry ana-
lyses show that cells grown for five passages homogenously
expressed SOX17 and CXCR4 (99%) similarly to hFSCs
generated fromhIPSCs proficient for endodermproduction
(BBHX8) (Figure 5A). Therefore, our culture system selec-
tively amplifies hFSCs even when they originate from a
heterogeneous population of DE cells. The resulting popu-
lation of hFSCs was expanded for two additional passages
and then transferred into culture conditions inductive for
pancreas and liver differentiation. Cells differentiated
toward the liver lineage expressed hepatic markers (AAT,
ALB, AFP, and HNF4a) at a level similar to hepatocyte-like
cells generated from control hFSCs (Figure 5B). Similarly,
cells differentiated toward the pancreatic lineage cells
expressed PDX1, INS, and NGN3 (Figure 5C). Together,
these results show that hFSCs can be easily generated
fromhIPSCs with reduced endoderm differentiation capac-
ity, enabling the production of hepatic and pancreatic cells.
Therefore, derivation of hFSCs could be achieved fromReports j Vol. 1 j 293–306 j October 15, 2013 j ª2013 The Authors 297
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Figure 3. hPSC-Derived Foregut Can Self-Renew In Vitro
(A) Method to differentiate and to propagate Foregut Stem Cells derived from hPSCs.
(B) Bright-field image of foregut stem cells growing as an epithelium.
(C and D) After ten passages, approximately 80% of hFSCs express Ki67.
(E) CGH profile of late-passage hFSCs showing no change in copy number.
(F) Growth curve of hFSCs.
(legend continued on next page)
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Figure 4. hFSCs Do Not Form Teratomas and Differentiate into Cells of the Foregut Only
(A) Large cystic hFSC outgrowth under the kidney capsule of a NOD-SCID mouse.
(B) Cryosection of a hFSC outgrowth showing large cystic structures lined with epithelial cells.
(C) Immunocytochemistry showing foregut outgrowths expressing EpCAM, PDX1, AFP, and NKX2.1.
Scale bars, 100 mm or 50 mm as shown. See also Figure S4.
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Multipotent Foregut Cells from Pluripotent Cellsnumerous hIPSC lines and enable us to bypass in part the
variability of hIPSC lines to generate hepatic/pancreatic
cells.DISCUSSION
Derivation of foregut stem cells with a strong proliferative
capacity as well as the ability to self-renew represents an
attractive cell source for multiple applications within the
regenerative medicine field, including disease modeling,
developmental studies, and cell-based therapies. Accord-
ingly, our results describe a stepwise method to differen-
tiate hPSCs into a multipotent population of foregut stem(G and H) qPCR and immunocytochemistry analyses showing that hFSC
grown for more than ten passages while maintaining the expression o
and SOX17). The expression of pluripotency (POU5F1, NANOG), pancre
observed during propagation.
(I) A near-homogenous population of hFSCs derived from both hESC- an
(C), (D), and (I) represent the number of positive cells counted from t
minimum of 100 cells per field normalized to the DAPI count. Scale b
Stem Cellcells. Importantly, production of foregut cells has been re-
ported previously (Green et al., 2011), but our study pro-
vides a culture system allowing the isolation, expansion,
and differentiation of multipotent self-renewing foregut
stem cells. Similarly, a recent study has shown that multi-
potent DE cells could be expanded in vitro (Cheng et al.,
2012; Sneddon et al., 2012), yet these cells express a broad
diversity of markers that render their embryonic identity
difficult to establish. Furthermore, these studies relied on
feeders, Matrigel, 3D culture conditions, or serum, any of
which is not compatible with large-scale or clinical applica-
tions. Nevertheless, hFSCs resemble mouse anterior defini-
tive endoderm cells isolated from mouse embryonic stem
cells using the combination of reporter gene for HEXs derived from hESCs (H9) and hIPSCs (BBHX8 and A1ATD-1) can be
f foregut markers (CERB, HNF1b, HNF6, CXCR4, GATA4, HHEX, HNF4a,
atic (PDX1), hepatic (AFP), lung (NKX2.1), and gut (CDX2) was not
d hIPSC-coexpressing foregut genes was evident after ten passages.
en random immunocytochemistry fields in three experiments with a
ars, 100 mm. Error bars represent SEM. See also Figure S3.
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Figure 5. hFSCs Have the Capacity to Differentiate into Multiple Derivatives of the Foregut
(A) Method to differentiate hFSCs into pancreatic cells.
(B) hFSCs grown in these culture conditions progressively express pancreatic bud markers (PDX1 and HLXB9) and then endocrine markers
(INS and NGN3). F, fetal pancreas; A, adult pancreas.
(C) C-peptide and PDX1 expression was confirmed by immunocytochemistry of cells differentiated for 25 days.
(legend continued on next page)
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Figure 6. Single hFSCs Are Multipotent
(A) GFP-expressing hPSCs were differentiated into hFSCs.
(B) Single GFP-positive hFSCs were seeded onto a layer of non-GFP hFSCs and then expanded for five passages. The resulting population was
then split into culture conditions inductive for liver or pancreatic differentiation.
(C and D) GFP-hFSCs differentiated for 25 days were found to respectively generate cells expressing liver markers (ALB, LDL-uptake) and
pancreatic markers (PDX1, C-peptide) from both hESC-derived (C) and hIPSC-derived (D) hFSCs.
Scale bars, 100 mm.
Stem Cell Reports
Multipotent Foregut Cells from Pluripotent Cellsexpression and the cell surface marker CXCR4 (Morrison
et al., 2008). In agreement, hFSCs display a similar gene
expression profile including the expression of HHEX and
CXCR4 and share a similar capacity of differentiation to-(D) Day 25 pancreatic cells released insulin into the medium when t
30 min.
(E) Method used to differentiate hFSCs into hepatic cells.
(F) After 25 days of differentiation, cells expressed hepatic markers
hepatocytes; F, fetal liver; A, adult liver).
(G) Expression of mature hepatocyte markers (ALB, A1AT, CK18, and
(H and I) Hepatocytes were capable of uptaking LDL from the medium
100 mm. ****p < 0.0001. Error bars represent SEM. See also Figures S
Stem Cellward liver and pancreas. However, hFSCs could also have
the unique capacity to generate lung/thyroid cells while
they have lost their capacity to generate gut cells. More
importantly, hFSCs can be easily isolated from a diversityreated with high-glucose Dulbecco’s modified Eagle’s medium over
(ALB, AFP, and A1AT). C, undifferentiated hESC; Hep, hFSC-derived
HNF4a) was confirmed by immunocytochemistry.
(H) and secreted albumin (I). C, medium with no cells. Scale bars,
4–S6.
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Figure 7. Generation of hFSCs Overcomes Variability between hIPSC Lines
(A) FACS analyses showing the fraction of cells coexpressing the endoderm/foregut markers SOX17/CXCR4 before isolation (colored plot)
and after expansion (passage 5, black plot) of hFSCs generated from hIPSC lines with high (BBHX8) and low (CoxS8, CoxV3, and Line4)
endoderm differentiation capacity. Secondary only antibody only control, gray population.
(B and C) hIPSCs with low endoderm capacity of differentiation cannot differentiate into liver or pancreatic cells [COXS8(B), COXV3(B),
4(B)], while hFSCs generated from the same cells seven passages later can differentiate into cells expressing markers for hepatocytes
(A1AT, AFP, and ALB HNF4a) and pancreatic cells (GCG, PDX1, INS, NGN3) at levels comparable to positive control (BBHX8).
Error bars represent SEM.
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Multipotent Foregut Cells from Pluripotent Cellsof hPSCs lines without the need for cell sorting and com-
plex genetic modifications, thereby allowing the produc-
tion of a near-homogenous population of cells with clinical
value. Overall, the hFSC culture system addresses several
important limitations associated with current methods
available to isolate and to expand endodermal stem cells.
hFSCs also share fundamental characteristics with their
in vivo counterpart, including the expression of key
markers such as FOXA2, CXCR4, HHEX, SOX17, and
CERB. Nevertheless, the exact type of foregut cell302 Stem Cell Reports j Vol. 1 j 293–306 j October 15, 2013 j ª2013 The Adescribed here is yet to be fully defined, as lineage tracing
experiments have shown that foregut may contain only
bipotential progenitors able to differentiate toward the
hepatic and pancreatic lineages (Deutsch et al., 2001).
However, the property of in vivo progenitors is likely to
be dictated by their localization within the foregut and
thus their surrounding environment. Moreover, the gut
tube initially possesses a high degree of plasticity. Indeed,
the hindgut domain, if taken at an early time point, is
capable of producing liver and pancreatic bud structuresuthors
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Multipotent Foregut Cells from Pluripotent Cellswhen either juxtaposed against foregut cardiac mesoderm
or placed in culture conditions with BMP and FGF (Bossard
and Zaret, 2000; Wells and Melton, 2000). This suggests
that during the early stages of gut formation, the entire
gut epithelial sheet could be multipotent. Thus, the cul-
ture system described here could be less restrictive,
enabling hFSCs to display the full range of their develop-
mental plasticity.
Self-renewing and multipotent adult stem cells could
represent an advantageous source for the generation of
large quantity of ‘‘safer’’ differentiated cells required for
cellular therapy, because they could strongly reduce the
risk of teratomas associated with pluripotent stem cells.
However, it is important to underline that the isolation
and serial passage of hFSCs did not improve the overall
maturity of the end-stage population after differentiation,
whether this be liver, lung, or pancreatic cells. Indeed, he-
patocytes or pancreatic cells generated from either freshly
derived foregut cells or P10 hFSCs still display a combina-
tion of adult and fetal characteristics and are not fully func-
tional with regard to cytochrome P450 activity or insulin
secretion, respectively. These results are in agreement
with a broad number of studies that have demonstrated
that fetal-like pancreatic/hepatic cells can be efficiently
generated from hPSCs (Cho et al., 2012; Hannan et al.,
2013; Rashid et al., 2010; Touboul et al., 2010) or from or-
gan-specific progenitors (Cardinale et al., 2011; D’Amour
et al., 2006; Deutsch et al., 2001; Morrison et al., 2008; Si-
Tayeb et al., 2010; Sneddon et al., 2012; Sullivan et al.,
2010; Van Haute et al., 2009; Wang et al., 2013; Zhao
et al., 2009). Thus, the current report does not claim to
solve this major challenge or even to improve existing pro-
tocol of differentiation. Our study only establishes that
hFSCs are able to produce liver and pancreas cells similar
to those generated from endodermal cells directly pro-
duced from hESCs (Cho et al., 2012; D’Amour et al.,
2006; Hannan et al., 2013; Rashid et al., 2010; Si-Tayeb
et al., 2010; Sneddon et al., 2012; Sullivan et al., 2010; Tou-
boul et al., 2010; Van Haute et al., 2009; Zhao et al., 2009).
The generation of fully functional cells from hPSCs re-
mains a distant goal that will require the development of
innovative approaches far beyond the scope of this work
(Shan et al., 2013; Takebe et al., 2013).
To conclude, expansion of a multipotent foregut progen-
itor population is of considerable interest with regard to
clinical applications. Indeed, our culture system is compat-
ible with large-scale production of a near-homogenous
population of endodermal cells that could greatly simplify
the production of cells for cell-based therapy. Furthermore,
derivation of hFSCs allowed for differentiation of all the
tested hIPSC lines without the need to establish individual
protocols. Therefore, hFSCs not only provide a unique
in vitro model of human development but also representStem Cellan important tool to deliver the clinical promises of hIPSCs
in the field of personalized medicine.EXPERIMENTAL PROCEDURES
Generation of hIPSCs
hIPSCs (BBHX8 and A1TATD) were derived using retrovirus-medi-
ated reprogramming of human skin fibroblasts using the Yama-
naka factors as described elsewhere (Rashid et al., 2010). Approval
for the collection of human tissue samples was obtained from the
NorthWest Ethics Committee (13/NW/0205). All animal work was
carried out with full home-office approval (project license 80/
2397).
Generation of GFP hPSCs and Clonal Analyses
GFP-expressing H9, BBHX8, and A1ATD-1 cells were generated by
stable transfection using lipofectamine 2000 (Invitrogen) as
described previously (Vallier et al., 2001). GFP-positive cells were
differentiated into foregut cells and then dissociated into single
cells. An individually isolated GFP cell was then transferred into
a well containing non-GFP-positive hFSCs. Wells were visually in-
spected 12 hr after plating, and wells containing a single GFP-pos-
itive hFSC were selected for clonal expansion.
Human Embryonic Stem and Induced Pluripotent
Stem Cell Culture
hESCs (H9) and hIPSCs (BBHX8, A1ATD-1, COXV3, COXS8,
Line4, and IPS40) were cultured in a chemically defined, feeder-
free culture system as described previously using activin-A
(10 ng/ml) and bFGF (12 ng/ml) (Brown et al., 2011; Rashid
et al., 2010; Teo et al., 2011; Vallier et al., 2009a; Vallier et al.,
2009b). Cells were passaged every 7 days using a mixture of colla-
genase IV or collagenase and dispase at a ratio of 1:1.
Differentiation of hPSCs into Endoderm
Cells were differentiated into definitive endodermusingCDM-PVA
and activin-A (100 ng/ml), BMP4 (10 ng/ml), bFGF (20 ng/ml), and
LY294002 (10 mM) for 3 days as described previously (Cho et al.,
2012; Rashid et al., 2010; Vallier et al., 2009a; Yusa et al., 2011).
Patterning of Definitive Endoderm
DE cells were cultured in RPMI+B27 medium with activin-A
(50 ng/ml) for 3-4 days to generate foregut cells. DE cells were
cultured in RPMI+B27 medium with CHIR99021 (6 mM) for
4 days to generate posterior endoderm.
Differentiation of Posterior Endoderm into 3D Gut
Organoids
Posteriorized endodermal cells were embedded in growth-factor-
reduced Matrigel (BD Biosciences) containing B27 supplement
(RA depleted) (Invitrogen), human R-spondin (500 ng/ml)
(R&D), human Noggin (100 ng/ml) (R&D), human EGF
(100 ng/ml) (R&D), and Jagged-1 peptide (1mM) (AnaSpec). Cell/
Matrigel mix was overlayed with Advanced Dulbecco’s modified
Eagle’s medium (DMEM)/F12 (Gibco) supplemented with 2 mMReports j Vol. 1 j 293–306 j October 15, 2013 j ª2013 The Authors 303
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Multipotent Foregut Cells from Pluripotent CellsGlutaMax (Invitrogen), 10 mMHEPES (Invitrogen), and 100 U/ml
penicillin per 100 mg/ml streptomycin containing B27 supplement
(RA depleted) (Invitrogen), Y-27632 (10 mM) (Sigma Aldrich),
Noggin (100 ng/ml) (R&D), human EGF (100 ng/ml) (R&D), hu-
man R-spondin (1 mg/ml) (R&D), and human Wnt3a (100 ng/ml)
(R&D).
Passaging and Maintenance of hFSCs
hFSCs were cultured on gelatine coated plates prepared as
described for hPSC maintenance in RPMI medium containing
B27 Supplement, NEAA, penicillin/streptomycin, activin-A
(10 ng/ml), bFGF (20 ng/ml), BMP (10 ng/ml), HGF (20 ng/ml),
and EGF (50 ng/ml). Cells were passaged every 4–7 days using
cell dissociation buffer (CDB). Cells were washed once with PBS
then incubated in CDB at 37C for 10–15 min. Cells were scraped
as small clumps and transferred to a 15 ml tube and centrifuged at
800 rpm for 2 min. Cells were washed once with RPMI medium
and then resuspended in RPMI medium containing the cocktails
of growth factors described above and ROCK inhibitor Y-27632
(10 mM). Cells were plated at a density of 40–60 3 103 cells/cm2
of plate surface area. ROCK inhibitor was not used during subse-
quent days of culture. Medium was changed the following day
and every subsequent day until cells were 80%–90% confluent.
Differentiation of hFSCs into Hepatic Endoderm
Hepatic differentiation has been described previously (Cho et al.,
2012; Rashid et al., 2010; Yusa et al., 2011). Briefly, hFSCs were
cultured in RPMI + B27 containing BMP4 (10 ng/ml) and FGF10
(10 ng/ml) for 4 days. Cells were then cultured in hepatocyte basal
medium (Lonza) containing oncostatin M (50 ng/ml) and HGF
(50 ng/ml) for at least an additional 20 days.
Differentiation of hFSCs into Pancreatic Endoderm
hFSCs were differentiated into pancreatic endoderm using a five-
step process as described previously (Cho et al., 2012). During stage
1 (S1), hFSCs were cultured in Advanced DMEM (Invitrogen) sup-
plemented with SB-431542 (10 mM; Tocris), FGF10 (50 ng/ml; Au-
togenBioclear), all-trans retinoic acid (RA, 2 mM; Sigma) and
Noggin (50 ng/ml; R&D Systems) for 3 days. For stage 2 (S2), the
cells were cultured in Advanced DMEM supplemented with hu-
man FGF10 (50 ng/ml; AutogenBioclear), all-trans retinoic acid
(RA, 2 uM; Sigma), KAAD-cyclopamine (0.25 uM; Toronto Research
Chemicals), and Noggin (50 ng/ml; R&D Systems) for 3 days. For
stage 3 (S3), the cells were cultured in human FGF10 (50 ng/ml;
R&D Systems) for 3 days. For maturation of pancreatic progenitors
(stage 4 [S4]), cells were grown in Advanced DMEM + 1% vol/vol
B27 and DAPT (1 mM) for 3 days and for 3 additional days in
Advanced DMEM + 1% vol/vol B27 (stage 5 [S5]). During S4 and
the final stage (S5) of differentiation, medium devoid of insulin
was used so as not to interfere with immunocytochemistry and
ELISA assays. Additionally, only antibodies raised against C-pep-
tide were used to avoid potential false-positive results.
Immunocytochemistry
For a complete list of primary and secondary antibodies, please
refer to Table S1. hPSCs or their differentiated progenitors were
fixed for 20 min at 4C in 4% paraformaldehyde and then washed304 Stem Cell Reports j Vol. 1 j 293–306 j October 15, 2013 j ª2013 The Athree times in PBS. Cells were incubated for 20 min at room tem-
perature in PBST (0.1% Triton X-100; Sigma; in PBS) containing
10% donkey serum (Serotec) and subsequently incubated over-
night at 4C with primary antibody diluted in 1% donkey serum
in PBST. Cells were then washed three times in PBS and incubated
with secondary antibodies in 1% donkey serum in PBST for 2 hr at
room temperature. Unbound secondary antibody was removed by
three 5 min washes in PBS. Hoechst 33258 was added to the first
wash.
For immunocytochemistry on 3D organoids, organoids were
removed from Matrigel, fixed in 4% paraformaldehyde, and
embedded in 4% agarose before processing for paraffin sections.
Following antigen retrieval, samples were permeabilized with
0.5% Triton X-100 and blocked in 10% fetal bovine serum before
overnight incubation in primary antibody. Samples were washed
with PBS and incubated with secondary antibodies for 1 hr at
room temperature before being counterstained using DAPI. Sam-
ples were imaged using a Zeiss Imager M.2, equipped with Axio-
Cam MRm and MRc cameras and AxioVision software for image
capture.
Immunocytochemistry on cryosections was performed by dry-
ing sections at 37C for 30 min before antigen retrieval at 95C.
Cells were then fixed in 4% paraformaldehyde for 20 min before
they were blocked and permeabilized using a solution of 10%
donkey serum 0.01% Triton X-100 for 30 min. Primary and sec-
ondary antibodies were applied using a 1% donkey serum
0.001% Triton X-100 solution.Flow Cytometry
For a complete list of primary and secondary antibodies used for
flow cytometry, please refer to Table S1. Adherent cells were
washed twice in PBS and then incubated for 20 min at 37C in
cell dissociation buffer (Invitrogen). Cells were dissociated by
gentle pipetting and resuspended at approximately 0.1–1 3 106
cells/ml in PBS. Cells were pelleted and fixed by resuspending cells
in 4% paraformaldehyde solution at 4C for 20 min. Cells were
washed in PBS and thenblocked andpermeabilized in PBS contain-
ing 10% donkey serum and 0.01% Triton X-100. Cells were then
incubated in a solution of 1% donkey serum 0.001% Triton
X-100 containing the primary antibody. Cell were incubated for
at least 2 hr at room temperature or overnight at 4C. Cells were
then washed three times in PBS 1% donkey serum and incubated
with secondary antibodies in for 2 hr at room temperature. Un-
bound secondary antibody was removed by three to five washes
in PBS. Cells were then analyzed using a FACS Calibur machine
(BD Biosciences). All flow cytometry experiments were gated first
using unstained cells and then cells containing the secondary
antibody only. On all flow cytometry plots, the secondary-only
population is shown in gray. All gates shown on scatterplots and
histogram plots were set to the secondary-only control. All flow
cytometry was validated with immunocytochemistry to ensure
that false-positive or false-negative results were not recorded.ELISA
hESCs grown for 25 days in culture conditions inductive for
pancreatic specification were cultured in differentiation medium
without insulin for 24 hr prior to glucose stimulation. Cells wereuthors
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mented with 2.2 mM glucose referred to as ‘‘low glucose’’ condi-
tions (Invitrogen) for 60 min at 37C. Preincubated cells were
grown in DMEM containing 22 mM glucose, referred to as ‘‘high
glucose conditions’’ for 5, 10, or 30 min. Supernatants were
collected for determination of C-peptide release. ELISA analyses
were performed using theMercodia Ultrasensitive C-peptide ELISA
kit (Mercodia).
For albumin secretion assays, high binding surface COSTAR 96-
well plates (Corning) were coated overnight with affinity-purified
rabbit polyclonal antibodies against albumin (Abcam 87564) at
2 mg/ml in carbonate/bicarbonate buffer (Na2CO3/NAHCO3,
pH 9.5). After washing (0.9% w/v NaCl, 0.05% v/v Tween 20),
the plates were blocked for 2 hr in blocking buffer (PBS, 0.25%
w/v BSA, 0.05% v/v Tween 20). Culture medium was diluted in
blocking buffer, and 50 ml was added to each well and then incu-
bated for 2 hr. After washing, the wells were incubated with corre-
sponding monoclonal antibodies (1 mg/ml diluted in blocking
buffer) and incubated for 2 hr. Bound monoclonal antibodies
were detected with rabbit anti-mouse immunoglobulin G horse-
radish peroxidase-labeled antibody (Sigma Aldrich, 1:20,000) for
1 hr. The reaction was developed with TMB liquid substrate (Sigma
Aldrich) for 10 min in the dark and the reaction was stopped with
1MH2SO4. Absorbance was read at 450 nm on a Thermo-maxmi-
croplate reader (Molecular Devices).Uptake of LDL
The Dil-LDL staining kit was purchased from Cayman Chemicals
and the assay was performed according to the manufacturer’s
instructions.Statistics
All experiments were carried out at a minimum of three technical
triplicates. Data represent biological triplicates. All values are ex-
pressed as the mean ± SEM. Differences between means were as-
sessed by t test using Graph Pad Prism 6 software. p < 0.05 was
considered significant. All p values are indicated in figure legends.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, six figures, and two tables and can be found
with this article online at http://dx.doi.org/10.1016/j.stemcr.
2013.09.003.
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